INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Investors take note—big pharma has no physical assets to develop drugs, nor the skills required

Investors take note—big pharma has no physical assets to develop drugs, nor the skills required

Hedley's interview with TrialSite News

Hedley Rees's avatar
Hedley Rees
May 31, 2022
∙ Paid
9

Share this post

INSIDE PHARMA
INSIDE PHARMA
Investors take note—big pharma has no physical assets to develop drugs, nor the skills required
Share

Investors hold the key to stopping big pharma antics

There is one sure way to get the attention of big pharma—investors unhappy with the performance of their hard-earned cash injections (excuse the pun!).

The previous post below should have given you a flavour of the risks and potholes that scatter the big pharma landscape.

Inside Pharma
Big pharma’s 40-year love affair with outsourcing everything must end
[This is the thinking behind an interview with Megan Redshaw for TrialSite News yesterday evening, out next week] Hypothesis for the interview Big pharma’s 40-year love affair with outsourcing everything must end, otherwise investors will take their money elsewhere…
Read more
3 years ago · 6 likes · 1 comment · Hedley Rees

My TrialSite News interview with Megan Redshaw laid flesh on the bones of this love affair that has taken big pharma to the edge of failure. Investors need to hear about that. They may want to put their money elsewhere. In doing that, the world will be a far better place without it.

Drug Development Expert Says Pharma’s 40-Year Love Affair with Outsourcing Must End

Watch the video here.

Don’t let me spoil your fun by telling you more. All I would ask is if you feel moved to share the video on YouTube, that would be a wonderful thing :O).

Hedley

Leave a comment

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share